Repare Therapeutics (RPTX) announced that Steve Forte, Executive Vice President and CFO, has been appointed as President and CEO and to the Board of Directors effective April 11. He will serve in this new role in addition to his current role as the company’s CFO. Lloyd Segal has resigned as President, CEO and as a member of the Board of Directors effective April 11, in order to pursue other opportunities. Additionally, Sandra Alves, Vice President and Corporate Controller, has been promoted to Chief Accounting Officer. Prior to joining Repare, Forte served as CFO of Clementia Pharmaceuticals, an innovator in treatments for rare diseases, during which Clementia was acquired by Ipsen S.A. for $1.3B.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Cathie Wood’s ARK Invest Snaps Up Tesla Stock (TSLA) amid 42% Price Drop
- Repare Therapeutics: Strategic Focus and Financial Stability Underpin Buy Rating
- Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics
- Repare Therapeutics price target lowered to $5 from $10 at H.C. Wainwright
- Repare Therapeutics Focuses on Clinical Trials Amid Restructuring